Reference priceEUR €21.99Original source price: INR 1,999.00. Converted estimates are available by currency selection.
| Brand | Ibrance |
|---|---|
| Manufacturer | Pfizer Pharma GmbH |
| Prescription required | Yes |
Ibrance 75mg Filmtabletten,3 x 7St(Palbociclib)
Palbociclib
Description
Ibrance 75mg Filmtabletten,3 x 7St(Palbociclib) is a medicine catalog record in the MediPriceHub database. Active ingredient: Palbociclib. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Pfizer Pharma GmbH. Therapeutic category: Medicine Library > Oncology Medicines > Breast Cancer Drugs. Pack information: 75 3 x 7. Origin country or market: Germany. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ; or o fulvestrant in patients with disease progression following endocrine therapy. o an aromatase inhibitor as initial endocrine-based therapy ; or o fulvestrant in patients with disease progression following endocrine therapy. • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA‑authorized test, following recurrence on or after completing adjuvant endocrine therapy. • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced or metastatic breast cancer following induction treatment.How to Use
Use Palbociclib under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: Palbociclib. Pack size: 75 3 x 7. Pack unit: box. Manufacturer: Pfizer Pharma GmbH. Origin country: Germany. Source category: Medicine Library > Oncology Medicines > Breast Cancer Drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Diese Angaben dienen nur als Referenz. Lassen Sie sich vor der Anwendung eines Medikaments von medizinischem Fachpersonal beraten.